Search Within

Gastrointestinal Oncology Service

Formats
  1. Journal Article (2350)
  2. Meeting Abstract (1870)
  3. Review (150)
  4. Book Section (127)
  5. Editorial (100)
  6. Guidelines (39)
  7. Correspondence (34)
  8. Conference Paper (24)
  9. Miscellaneous (23)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Solid Tumor Oncology Division (4746)
  2. Department of Medicine (4744)
  3. Center for Pancreatic Cancer Research (2313)
  4. Surgery (1066)
  5. Survivorship Research (1014)
  6. Epidemiology and Biostatistics (842)

More Groups

People
  1. Eileen O'Reilly (803)
  2. Leonard Saltz (796)
  3. Ghassan Abou-Alfa (583)
  4. Nancy Kemeny (545)
  5. David Kelsen (538)
  6. David Ilson (443)

More People

Years
  1. 2025 (221)
  2. 2024 (309)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1290)
  2. Annals of Oncology (331)
  3. Annals of Surgical Oncology (148)
  4. Cancer (128)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1379)
  2. Oxford University Press (462)
  3. Elsevier Inc. (408)
  4. Springer (321)
  5. American Association for Cancer Research (281)
  6. Wiley Blackwell (241)

More Publishers

Results (4746)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Combining transcriptomic- and tissue-based immune biomarkers to evaluate GB1275, a CD11b modulator, as a single agent or with pembrolizumab in patients with advanced solid tumors
    Meeting Abstract

    Messersmith, W.; Rasco, D.; De Bono, J.; Wang-Gillam, A.; Park, W.; Nickle, D.; Galkin, A.; Ferguson, B.; Carter, L.; Zhou, L.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • CDX1140-01, a phase 1 dose-escalation/expansion study of CDX-1140 alone (part 1) and in combination with CDX-301 (part 2) or pembrolizumab (part 3)
    Meeting Abstract

    Sanborn, R.; Hauke, R.; Gabrail, N.; O'Hara, M.; Bhardwaj, N.; Bordoni, R.; Gordon, M.; Khalil, D.; Abdelrahim, M.; Marron, T.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Preliminary results from Keynote-A36, a study of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab or chemotherapy in specified advanced solid tumors
    Meeting Abstract

    Bendell, J.; Messersmith, W.; Rasco, D.; Wang-Gillam, A.; Park, W.; Zhou, L.; Carter, L.; Bruey, J. M.; Li, J.; Ferguson, B.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Phase IB/II open-label, randomized evaluation of atezolizumab (atezo) plus selicrelumab (seli) plus gemcitabine plus nab-paclitaxel (gem plus nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRC
    Meeting Abstract

    Manji, G.; Bahary, N.; Chung, V.; Dalenc, F.; Ducreux, M.; Gomez-Roca, C.; Im, S. A.; Kortmansky, J.; Lacy, J.; Segal, N.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Generalizability of potential biomarkers of response to CTLA-4 and PD-1 blockade therapy in cancer
    Meeting Abstract

    Bortone, D.; Vensko, S.; Entwistle, S.; Cogdill, A.; Monette, A.; Najjar, Y.; Sweis, R.; Tschernia, N.; Wennerberg, E.; Bommareddy, P.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • L1CAM defines the regenerative origin of metastasis-initiating cells in colorectal cancer
    Journal Article

    Ganesh, K.; Basnet, H.; Kaygusuz, Y.; Laughney, A. M.; He, L.; Sharma, R.; O'Rourke, K. P.; Reuter, V. P.; Huang, Y. H.; Turkekul, M.; more...
    Nature Cancer (2020)

    Fulltext@MSK | Save
  • A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma
    Journal Article

    Hayashi, A.; Fan, J.; Chen, R.; Ho, Y. J.; Makohon-Moore, A. P.; Lecomte, N.; Zhong, Y.; Hong, J.; Huang, J.; Sakamoto, H.; more...
    Nature Cancer (2020)

    Fulltext@MSK | Save
  • Weight-based dosing of pembrolizumab every 6 weeks in the time of COVID-19
    Editorial

    Goldstein, D. A.; Ratain, M. J.; Saltz, L. B.
    JAMA Oncology (2020)

    Fulltext@MSK | Save
  • Association of coffee intake with survival in patients with advanced or metastatic colorectal cancer
    Journal Article

    Mackintosh, C.; Yuan, C.; Ou, F. S.; Zhang, S.; Niedzwiecki, D.; Chang, I. W.; O'Neil, B. H.; Mullen, B. C.; Lenz, H. J.; Blanke, C. D.; more...
    JAMA Oncology (2020)

    Fulltext@MSK | Save
  • Body mass index and weight loss in metastatic colorectal cancer in CALGB (Alliance)/SWOG 80405
    Journal Article

    Guercio, B. J.; Zhang, S.; Venook, A. P.; Ou, F. S.; Niedzwiecki, D.; Lenz, H. J.; Innocenti, F.; Mullen, B. C.; O'Neil, B. H.; Shaw, J. E.; more...
    JNCI Cancer Spectrum (2020)

    Fulltext@MSK | Save